Neomorph Appoints Dr. Klaus Wagner as New Chief Medical Officer

Neomorph's Significant Leadership Addition

Neomorph, Inc., an innovator in biotechnology, has announced the appointment of Dr. Klaus Wagner as its new Chief Medical Officer (CMO). With an impressive track record in the biotech industry, Dr. Wagner is set to propel Neomorph's ambitious goals forward, particularly in the field of oncology therapeutics.

With a career dedicated to guiding the development of cancer treatments, Dr. Wagner has previously served as CMO at Boundless Bio, Inc. During his tenure there, he played a pivotal role in the clinical development of small molecule therapies designed for patients with oncogene amplifications. Dr. Wagner’s past experience at Inhibrx, Inc. saw him build and lead a clinical development organization, where he successfully advanced multiple therapeutic candidates from the pre-Investigational New Drug (IND) stage into clinical trials including several oncology programs.

Phil Chamberlain, DPhil., the Co-Founder, President, and CEO of Neomorph, expressed enthusiasm regarding Dr. Wagner's addition to the team. He noted how Dr. Wagner's extensive oncology expertise aligns with Neomorph's commitment to revolutionizing cancer treatment. “His contributions will not only enhance our existing pipeline but also bolster the development of our emerging portfolio of assets,” said Chamberlain.

Cam Wheeler, Partner at Deerfield Management and Chair of Neomorph's Board of Directors, echoed the sentiments shared by Chamberlain, labeling Dr. Wagner as an exceptional addition to the Neomorph team. With a background as both an oncologist and an accomplished drug developer, Dr. Wagner's knowledge will greatly aid Neomorph’s transition into the realm of development-stage biotechnology.

In his own words, Dr. Wagner emphasized the urgency for meaningful advancements in cancer treatment options, stating, “Cancer patients with currently intractable therapeutic targets are in desperate need of better treatment options.” He is particularly enthusiastic about the potential of Neomorph’s groundbreaking targeted protein degrader and molecular glue technology, which he believes can address an expansive range of therapeutic targets.

Dr. Wagner is board-certified in Medical Oncology and continues to treat cancer patients, having worked at the esteemed Banner MD Anderson Cancer Center. Additionally, he has served as an Adjunct Assistant Professor within the Department of Thoracic, Head, and Neck Medical Oncology at MD Anderson, where he was instrumental in leading trials that explored molecularly targeted therapies and immunotherapy approaches for non-small cell lung cancer. His stellar career has also included impactful research roles at Genentech, Inc. and the Novartis Research Foundation, targeting cancer drug development and biomarker discovery.

Dr. Wagner earned both his M.D. and Ph.D. from Friedrich-Alexander University of Erlangen in Germany, and was recognized as a scholar by the German National Academic Scholarship Foundation. He completed his fellowship in Medical Oncology at MD Anderson Cancer Center, further solidifying his expertise in the field.

About Neomorph

Founded in 2020, Neomorph, Inc. is a biotechnology company committed to tackling critical health challenges through the development of innovative therapies targeting 'undruggable' proteins. Backed by venture capital firm Deerfield Management Company, Neomorph boasts a team of industry-leading experts in protein degradation and molecular glue technologies, consistently pushing forward the frontiers of drug discovery.

The company's headquarters is located in San Diego, California, where its team continues to drive the science and technology of molecular glue drug discovery while navigating its exciting pipeline of clinical projects. For further information about Neomorph and its mission, please visit Neomorph's website or follow them on LinkedIn.